Legend Biotech Corporation
19.91USD
-0.5800 (-2.83%)
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $0.01▼ | $0.1 | 0 | 1 |
| Next quarter | $0.09▼ | $0.16 | 0 | 1 |
| Current year | $-0.01▼ | $0.28 | 0 | 1 |
| Next year | $0.88▼ | $1.3 | 0 | 1 |
Beat in 1 of the last 3
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $0.28 | $0.32 | +0.04 (+14.3%) |
| 2025-12-31 | $0.19 | $-0.16 | -0.35 (-184.4%) |
| 2025-09-30 | $-0.19 | $-0.22 | -0.04 (-18.9%) |
142 ratings from 23 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| HC Wainwright & Co. | Reiterated | Buy | $65 | Sep 4, 2026 |
| Morgan Stanley | Maintained | Overweight | $48 $49 | Aug 12, 2026 |
| TD Cowen | Maintained | Hold | $29 $24 | Aug 12, 2026 |
| Oppenheimer | Downgraded from Outperform | Perform | $75 $40 | Aug 12, 2026 |
| RBC Capital | Maintained | Outperform | $59 $58 | Aug 12, 2026 |
| Barclays | Maintained | Overweight | $80 $78 | Aug 12, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $65 | Jul 28, 2026 |
| RBC Capital | Maintained | Outperform | $63 $59 | Jul 27, 2026 |
| UBS | Downgraded from Buy | Neutral | $49 $28 | Jul 24, 2026 |
| RBC Capital | Maintained | Outperform | $64 $63 | Jul 7, 2026 |
| UBS | Maintained | Buy | $31 $49 | Jun 3, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $50 $65 | Jun 3, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $50 | May 18, 2026 |
| TD Cowen | Maintained | Hold | $21 $29 | May 13, 2026 |
| Morgan Stanley | Maintained | Overweight | $49 $48 | May 13, 2026 |
| RBC Capital | Maintained | Outperform | $62 $64 | May 13, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $50 | Apr 21, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $50 | Apr 15, 2026 |
| Morgan Stanley | Maintained | Overweight | $50 $49 | Mar 11, 2026 |
| RBC Capital | Maintained | Outperform | $66 $62 | Mar 11, 2026 |
| Barclays | Maintained | Overweight | $90 $80 | Feb 4, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $60 $50 | Jan 22, 2026 |
| TD Cowen | Downgraded from Buy | Hold | $62 $21 | Jan 22, 2026 |
| RBC Capital | Maintained | Outperform | $66 | Jan 20, 2026 |
| Oppenheimer | Initiated | Outperform | $75 | Jan 7, 2026 |
4 filings from 3 insiders · 2 buy / 2 sell over 6m
Officers and directors of LEGN, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| BASH ALANChief Executive Officer | Grant | 4.9k | — | — | Aug 14, 2026 |
| CASEY PATRICK JOHN PH.D.Director | Sell | 6.0k | $28.88 | $173k | Jun 30, 2026 |
| HUANG YINGChief Executive Officer | Gift | 3.4k | — | — | Jun 30, 2026 |
| HUANG YINGChief Executive Officer | Sell | 5.6k | $28.43 | $158k | Jun 25, 2026 |
No analyst notes on LEGN yet.
Analyst Ratings
15 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 5 | 5 | 5 | 0 | 0 | Buy2.00 |
| 1 mo ago | 5 | 5 | 5 | 0 | 0 | Buy2.00 |
| 2 mo ago | 5 | 6 | 4 | 0 | 0 | Buy1.93 |
| 3 mo ago | 5 | 7 | 2 | 0 | 0 | Buy1.79 |